Global Joint Pain Injection Market - 2025 -2033
Joint Pain Injection Market Size
In 2023, the global joint pain injection market was valued at US$ 4.60 Billion. The global Joint Pain Injection market size reached US$ 5.08 Billion in 2024 and is expected to reach US$ 13.51 Billion by 2033, growing at a CAGR of 11.6% during the forecast period 2025-2033.
Global Joint Pain Injection Market Overview
The global market for joint pain injections is experiencing steady expansion, driven by rising cases of osteoarthritis (OA) and growing demand for minimally invasive, non-opioid alternatives to manage chronic musculoskeletal pain. As the global elderly population rises and sedentary lifestyles increase among younger demographics, joint degeneration and related disorders are becoming increasingly common. Intra-articular injection therapies are gaining traction as effective outpatient treatments with reduced recovery time. These therapies are now recognized not just for symptom relief, but also for their regenerative potential and ability to delay or reduce the need for surgical interventions.
A strong shift in patient and clinician preference away from long-term opioid usage and invasive joint replacement surgeries is contributing to the market’s sustained momentum. Increased healthcare awareness, improved insurance coverage, and a growing number of orthopedic specialists offering advanced injectable options are all contributing to expanding global adoption. Market players are increasingly investing in formulation innovations and aligning with a broader industry trend toward personalized, targeted pain management strategies.
In 2024, the U.S. Joint Pain Injection Market was valued at USD 1.51 billion and is expected to reach USD 4.02 billion by 2033. This growth is being powered by high OA prevalence, rising outpatient utilization of PRP and viscosupplementation therapies, and broadening insurance reimbursement policies. Advanced delivery devices and increasing clinical trials in regenerative medicine are further fueling innovation across North America.
The market in Japan, which has one of the oldest populations globally, is benefiting from widespread use of hyaluronic acid injections for knee OA and a national healthcare system that supports non-surgical interventions. Japan’s orthopedic community is also driving adoption of next-gen biologicals, while its patients increasingly seek outpatient solutions that allow continued mobility and avoid long hospital stays.
Global Joint Pain Injection Market Dynamics: Drivers & Restraints
Market Dynamics
Key Drivers: With the growing burden of osteoarthritis and other degenerative joint conditions, joint pain injections are becoming a core component of non-surgical pain management strategies.
These injections, ranging from corticosteroids and hyaluronic acid to platelet-rich plasma (PRP), are gaining traction due to their fast-acting relief, minimally invasive nature, and potential to delay or avoid joint replacement surgeries. The rise in aging populations globally, coupled with increased rates of obesity and sedentary lifestyles, is accelerating the demand. For instance, according to the CDC, approximately 1 in 5 U.S. adults is affected by some form of arthritis. Among the more than 100 known types, osteoarthritis (OA) is the most prevalent, impacting around 32.5 million adults across the United States.
Particularly in orthopedic clinics and outpatient care centers, injections are preferred for their ability to target localized pain without systemic drug exposure.
Hyaluronic acid injections, for example, are now considered a first-line treatment for moderate osteoarthritis in many regions due to their extended duration of relief compared to oral medications.
Restraints:
Limited long-term efficacy is hampering the growth of the Joint Pain Injection market
Inconsistent long-term efficacy of joint injections continues to limit market expansion in broader patient groups.
Most commonly used treatments, such as corticosteroids or Visco supplementation, provide only temporary relief, often requiring repeat procedures. This not only increases cumulative healthcare costs but also raises concerns about cartilage deterioration and side effects with repeated usage.
Furthermore, the limited insurance coverage for some emerging biologics, like PRP or stem cell injections, creates a financial barrier for both providers and patients, restricting wider adoption across general orthopedic and primary care settings.
Opportunities:
Emerging biologic injections are expected to create a lucrative opportunity for the growth of the Joint Pain Injection market
The emergence of biologic and regenerative injections presents new growth horizons for joint pain injection therapy.
Advanced treatments such as PRP, stem cell therapies, and orthobiologics are gaining attention for their regenerative potential, offering not just symptom relief but also biological repair of damaged tissues. These modalities are being increasingly adopted by sports medicine practitioners and orthopedic specialists to treat early-stage joint degeneration, especially among younger and more active patients.
The growing consumer preference for non-opioid, personalized therapies is also fueling investment and innovation in this space, with biotech companies exploring novel formulations and delivery systems.
Global Joint Pain Injection Market, Segment Analysis
The global joint pain injection market is segmented based on injection type, joint type, cause, distribution channel, and region.
By Injection Type
The hyaluronic acid (HA) segment in the joint pain injection was valued at US$ 1.64 Billion in 2024
Hyaluronic Acid Injections accounted for the largest revenue share in 2024, representing 32.4% of the global joint pain injection market. The widespread use of HA in treating knee osteoarthritis, especially under FDA-approved brands such as Synvisc, Monovisc, and Euflexxa, has driven adoption across orthopedic and sports clinics.
Patients and physicians favor HA due to its longer pain relief window and fewer side effects compared to corticosteroids. Hyaluronic acid (HA) injections currently dominate the joint pain injection market due to their widespread clinical use, regulatory approval, and proven efficacy in managing osteoarthritis, particularly of the knee.
Platelet-Rich Plasma (PRP) Injections:
Platelet-Rich Plasma (PRP) injections are projected to grow fast from 2025 to 2033. As a key player in the biologics space, PRP is gaining ground among younger patients and athletes seeking regenerative solutions. Clinics offering sports medicine and advanced orthopedics are pioneering the use of PRP for early intervention, helping the segment expand rapidly.
By Distribution Channel
Hospital Pharmacies led the distribution segment with the largest revenue share in 2024 due to their proximity to treatment facilities and integration with prescription workflows.
Online Pharmacies and Specialty Drug Distributors are growing at a robust pace, offering convenience for providers and direct-to-clinic deliveries.
Global Joint Pain Injection Market, Geographical Analysis
North America was valued at US$ 2.01 Billion in 2024 with a significant portion in the global joint pain injection market
North America dominated the joint pain injection market in 2024, accounting for over 39.70% of global revenue. This leadership is driven by advanced healthcare infrastructure, high awareness of joint pain therapies, and favorable reimbursement policies, particularly for HA and corticosteroid injections. The U.S. leads the region, supported by a large elderly population, increasing sports injuries, and a strong presence of key players such as Zimmer Biomet, Anika Therapeutics, and Bioventus. Additionally, the rapid integration of biologics into orthopedic care pathways is positioning North America as the innovation hub for joint injection therapies.
Ongoing clinical research and high awareness among both physicians and patients further solidify North America’s leadership in the joint pain injection market. These real-time factors together are driving the region’s dominance in the global joint pain injection market.
Asia-Pacific is growing at the fastest pace in the joint pain injection market, holding 21.4% of the market share
Asia-Pacific is expected to be the fastest-growing region from 2025 to 2033. Rapid aging in countries like Japan, China, and South Korea, combined with increased healthcare investments and growing patient awareness, is accelerating adoption. The region is also seeing growing interest in regenerative medicine, particularly PRP and stem cell therapies, driven by supportive regulatory frameworks and government-backed medical innovation hubs.
China is leading this regional surge with expanded orthopedic services and an increase in clinical adoption of both traditional and biologic joint injection products.
Europe
Europe holds a strong share in the joint pain injection market, backed by public healthcare access, aging demographics, and wide physician adoption of HA and corticosteroid injections. Countries like Germany and France are increasingly exploring biologics for orthopedic use, supported by clinical research institutions and collaborations with biotech firms.
Germany stands out as the regional leader due to its strong orthopedic network, regulatory clarity, and advanced manufacturing ecosystem for HA-based products.
Middle East & Africa / South America
Both regions are witnessing steady adoption driven by urbanization, increased orthopedic diagnoses, and expanding private healthcare sectors. The UAE and Brazil, in particular, are investing in smart clinics and sports medicine centers that are incorporating advanced injection therapies for joint pain management.
Global Joint Pain Injection Market Competitive Landscape
Top companies in the joint pain injection market include Bioventus, Anika Therapeutics Inc., Zimmer Biomet, Dr. Reddy’s Laboratories Ltd., and Fidia Farmaceutici S.p.A., among others.
Global Joint Pain Injection Market Key Developments
DMI recommends that companies concentrate on high-growth biologics, such as PRP and orthobiologics, rather than conventional corticosteroids, which are ineffective in the long term. In 2024, North America will comprise 39.7% of the market. Businesses should incorporate additional biologics into their portfolios that are targeted at ambulatory and sports medicine clinics due to the robust reimbursement support. Japan and China are optimal investment destinations for the foreseeable future due to the geriatric populations and the increasing prevalence of non-surgical OA therapies. In order to distinguish oneself, it will be necessary to allocate funds toward innovative service delivery methods, payer engagement, and outcome-focused research. Access and profit margins can be further enhanced through online and specialized distribution.
The global joint pain injection market report delivers a detailed analysis with 50+ key tables, more than 60+ visually impactful figures, and 178 pages of expert insights, providing a complete view of the market landscape.
In 2023, the global joint pain injection market was valued at US$ 4.60 Billion. The global Joint Pain Injection market size reached US$ 5.08 Billion in 2024 and is expected to reach US$ 13.51 Billion by 2033, growing at a CAGR of 11.6% during the forecast period 2025-2033.
Global Joint Pain Injection Market Overview
The global market for joint pain injections is experiencing steady expansion, driven by rising cases of osteoarthritis (OA) and growing demand for minimally invasive, non-opioid alternatives to manage chronic musculoskeletal pain. As the global elderly population rises and sedentary lifestyles increase among younger demographics, joint degeneration and related disorders are becoming increasingly common. Intra-articular injection therapies are gaining traction as effective outpatient treatments with reduced recovery time. These therapies are now recognized not just for symptom relief, but also for their regenerative potential and ability to delay or reduce the need for surgical interventions.
A strong shift in patient and clinician preference away from long-term opioid usage and invasive joint replacement surgeries is contributing to the market’s sustained momentum. Increased healthcare awareness, improved insurance coverage, and a growing number of orthopedic specialists offering advanced injectable options are all contributing to expanding global adoption. Market players are increasingly investing in formulation innovations and aligning with a broader industry trend toward personalized, targeted pain management strategies.
In 2024, the U.S. Joint Pain Injection Market was valued at USD 1.51 billion and is expected to reach USD 4.02 billion by 2033. This growth is being powered by high OA prevalence, rising outpatient utilization of PRP and viscosupplementation therapies, and broadening insurance reimbursement policies. Advanced delivery devices and increasing clinical trials in regenerative medicine are further fueling innovation across North America.
The market in Japan, which has one of the oldest populations globally, is benefiting from widespread use of hyaluronic acid injections for knee OA and a national healthcare system that supports non-surgical interventions. Japan’s orthopedic community is also driving adoption of next-gen biologicals, while its patients increasingly seek outpatient solutions that allow continued mobility and avoid long hospital stays.
Global Joint Pain Injection Market Dynamics: Drivers & Restraints
Market Dynamics
Key Drivers: With the growing burden of osteoarthritis and other degenerative joint conditions, joint pain injections are becoming a core component of non-surgical pain management strategies.
These injections, ranging from corticosteroids and hyaluronic acid to platelet-rich plasma (PRP), are gaining traction due to their fast-acting relief, minimally invasive nature, and potential to delay or avoid joint replacement surgeries. The rise in aging populations globally, coupled with increased rates of obesity and sedentary lifestyles, is accelerating the demand. For instance, according to the CDC, approximately 1 in 5 U.S. adults is affected by some form of arthritis. Among the more than 100 known types, osteoarthritis (OA) is the most prevalent, impacting around 32.5 million adults across the United States.
Particularly in orthopedic clinics and outpatient care centers, injections are preferred for their ability to target localized pain without systemic drug exposure.
Hyaluronic acid injections, for example, are now considered a first-line treatment for moderate osteoarthritis in many regions due to their extended duration of relief compared to oral medications.
Restraints:
Limited long-term efficacy is hampering the growth of the Joint Pain Injection market
Inconsistent long-term efficacy of joint injections continues to limit market expansion in broader patient groups.
Most commonly used treatments, such as corticosteroids or Visco supplementation, provide only temporary relief, often requiring repeat procedures. This not only increases cumulative healthcare costs but also raises concerns about cartilage deterioration and side effects with repeated usage.
Furthermore, the limited insurance coverage for some emerging biologics, like PRP or stem cell injections, creates a financial barrier for both providers and patients, restricting wider adoption across general orthopedic and primary care settings.
Opportunities:
Emerging biologic injections are expected to create a lucrative opportunity for the growth of the Joint Pain Injection market
The emergence of biologic and regenerative injections presents new growth horizons for joint pain injection therapy.
Advanced treatments such as PRP, stem cell therapies, and orthobiologics are gaining attention for their regenerative potential, offering not just symptom relief but also biological repair of damaged tissues. These modalities are being increasingly adopted by sports medicine practitioners and orthopedic specialists to treat early-stage joint degeneration, especially among younger and more active patients.
The growing consumer preference for non-opioid, personalized therapies is also fueling investment and innovation in this space, with biotech companies exploring novel formulations and delivery systems.
Global Joint Pain Injection Market, Segment Analysis
The global joint pain injection market is segmented based on injection type, joint type, cause, distribution channel, and region.
By Injection Type
The hyaluronic acid (HA) segment in the joint pain injection was valued at US$ 1.64 Billion in 2024
Hyaluronic Acid Injections accounted for the largest revenue share in 2024, representing 32.4% of the global joint pain injection market. The widespread use of HA in treating knee osteoarthritis, especially under FDA-approved brands such as Synvisc, Monovisc, and Euflexxa, has driven adoption across orthopedic and sports clinics.
Patients and physicians favor HA due to its longer pain relief window and fewer side effects compared to corticosteroids. Hyaluronic acid (HA) injections currently dominate the joint pain injection market due to their widespread clinical use, regulatory approval, and proven efficacy in managing osteoarthritis, particularly of the knee.
Platelet-Rich Plasma (PRP) Injections:
Platelet-Rich Plasma (PRP) injections are projected to grow fast from 2025 to 2033. As a key player in the biologics space, PRP is gaining ground among younger patients and athletes seeking regenerative solutions. Clinics offering sports medicine and advanced orthopedics are pioneering the use of PRP for early intervention, helping the segment expand rapidly.
By Distribution Channel
Hospital Pharmacies led the distribution segment with the largest revenue share in 2024 due to their proximity to treatment facilities and integration with prescription workflows.
Online Pharmacies and Specialty Drug Distributors are growing at a robust pace, offering convenience for providers and direct-to-clinic deliveries.
Global Joint Pain Injection Market, Geographical Analysis
North America was valued at US$ 2.01 Billion in 2024 with a significant portion in the global joint pain injection market
North America dominated the joint pain injection market in 2024, accounting for over 39.70% of global revenue. This leadership is driven by advanced healthcare infrastructure, high awareness of joint pain therapies, and favorable reimbursement policies, particularly for HA and corticosteroid injections. The U.S. leads the region, supported by a large elderly population, increasing sports injuries, and a strong presence of key players such as Zimmer Biomet, Anika Therapeutics, and Bioventus. Additionally, the rapid integration of biologics into orthopedic care pathways is positioning North America as the innovation hub for joint injection therapies.
Ongoing clinical research and high awareness among both physicians and patients further solidify North America’s leadership in the joint pain injection market. These real-time factors together are driving the region’s dominance in the global joint pain injection market.
Asia-Pacific is growing at the fastest pace in the joint pain injection market, holding 21.4% of the market share
Asia-Pacific is expected to be the fastest-growing region from 2025 to 2033. Rapid aging in countries like Japan, China, and South Korea, combined with increased healthcare investments and growing patient awareness, is accelerating adoption. The region is also seeing growing interest in regenerative medicine, particularly PRP and stem cell therapies, driven by supportive regulatory frameworks and government-backed medical innovation hubs.
China is leading this regional surge with expanded orthopedic services and an increase in clinical adoption of both traditional and biologic joint injection products.
Europe
Europe holds a strong share in the joint pain injection market, backed by public healthcare access, aging demographics, and wide physician adoption of HA and corticosteroid injections. Countries like Germany and France are increasingly exploring biologics for orthopedic use, supported by clinical research institutions and collaborations with biotech firms.
Germany stands out as the regional leader due to its strong orthopedic network, regulatory clarity, and advanced manufacturing ecosystem for HA-based products.
Middle East & Africa / South America
Both regions are witnessing steady adoption driven by urbanization, increased orthopedic diagnoses, and expanding private healthcare sectors. The UAE and Brazil, in particular, are investing in smart clinics and sports medicine centers that are incorporating advanced injection therapies for joint pain management.
Global Joint Pain Injection Market Competitive Landscape
Top companies in the joint pain injection market include Bioventus, Anika Therapeutics Inc., Zimmer Biomet, Dr. Reddy’s Laboratories Ltd., and Fidia Farmaceutici S.p.A., among others.
Global Joint Pain Injection Market Key Developments
- In September 2024, Sun Pharmaceutical Industries Limited and Moebius Medical Limited announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation (FTD) to MM-II (Large Liposomes of DPPC and DMPC) for the treatment of osteoarthritis knee pain. Planning for confirmatory Phase 3 clinical trials for MMII is underway.
DMI recommends that companies concentrate on high-growth biologics, such as PRP and orthobiologics, rather than conventional corticosteroids, which are ineffective in the long term. In 2024, North America will comprise 39.7% of the market. Businesses should incorporate additional biologics into their portfolios that are targeted at ambulatory and sports medicine clinics due to the robust reimbursement support. Japan and China are optimal investment destinations for the foreseeable future due to the geriatric populations and the increasing prevalence of non-surgical OA therapies. In order to distinguish oneself, it will be necessary to allocate funds toward innovative service delivery methods, payer engagement, and outcome-focused research. Access and profit margins can be further enhanced through online and specialized distribution.
The global joint pain injection market report delivers a detailed analysis with 50+ key tables, more than 60+ visually impactful figures, and 178 pages of expert insights, providing a complete view of the market landscape.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Injection Type
2.4. Snippet by Joint Type
2.5. Snippet by Cause
2.6. Snippet by Distribution Channel
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Osteoarthritis (OA)
3.1.1.2. Minimally Invasive Alternatives to Surgery
3.1.1.3. Rising Demand for Non-Opioid Pain Management Options
3.1.2. Restraints
3.1.2.1. Limited Long-Term Efficacy
3.1.2.2. High Treatment Costs
3.1.2.3. Regulatory Challenges
3.1.3. Opportunity
3.1.3.1. Emerging Biologic Injections
3.1.3.2. Expansion into Emerging Markets
3.1.3.3. Advances in extended-release Corticosteroids and Novel HA Formulations
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Pipeline Analysis
4.7. Patent Analysis
4.8. SWOT Analysis
4.9. Unmet Needs and Gaps
4.10. Recommended Strategies for Market Entry and Expansion
4.11. Pricing Analysis and Price Dynamics
5. GLOBAL JOINT PAIN INJECTION MARKET, BY INJECTION TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Injection Type
5.1.2. Market Attractiveness Index, By Injection Type
5.2. Hyaluronic acid (HA)*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Corticosteroids
5.4. Prolotherapy Injections
5.5. Orthobiologics
5.6. Platelet-rich Plasma (PRP) Injections
5.7. Others
6. GLOBAL JOINT PAIN INJECTION MARKET, BY JOINT TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Joint Type
6.1.2. Market Attractiveness Index, By Joint Type
6.2. Knee and Ankle*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Hip
6.4. Shoulder and Elbow
6.5. Others
7. GLOBAL JOINT PAIN INJECTION MARKET, BY CAUSE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cause
7.1.2. Market Attractiveness Index, By Cause
7.2. Osteoarthritis*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Rheumatoid arthritis
7.4. Fibromyalgia
7.5. Others
8. GLOBAL JOINT PAIN INJECTION MARKET, BY DISTRIBUTION CHANNEL
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Online Pharmacies
9. GLOBAL JOINT PAIN INJECTION MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Injection Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Joint Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cause
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.7.1. U.S.
9.2.7.2. Canada
9.2.7.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Injection Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Joint Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cause
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.1. Germany
9.3.7.2. UK
9.3.7.3. France
9.3.7.4. Spain
9.3.7.5. Italy
9.3.7.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Injection Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Joint Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cause
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.7.1. China
9.4.7.2. India
9.4.7.3. Japan
9.4.7.4. South Korea
9.4.7.5. Rest of Asia-Pacific
9.5. South America
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Injection Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Joint Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cause
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.7.1. Brazil
9.5.7.2. Argentina
9.5.7.3. Rest of South America
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Injection Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Joint Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cause
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
11.1. Key Players
11.1.1. Bioventus*
11.1.2. Company Overview
11.1.2.1. Product Portfolio
11.1.2.1.1. Product Description
11.1.2.1.2. Product Key Performance Indicators (KPIs)
11.1.2.2. Financial Overview
11.1.2.2.1. Company Revenue
11.1.2.2.2. Geographical Revenue Shares
11.1.2.2.3. Revenue Forecasts
11.1.2.3. Key Developments
11.1.2.3.1. Mergers & Acquisitions
11.1.2.3.2. Key Product Development Activities
11.1.2.3.3. Regulatory Approvals, etc.
11.1.2.4. SWOT Analysis
11.1.3. Anika Therapeutics Inc
11.1.4. Zimmer Biomet
11.1.5. Dr. Reddy’s Laboratories Ltd.
11.1.6. Fidia Farmaceutici S.p.A. (LIST NOT EXHAUSTIVE)
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Injection Type
2.4. Snippet by Joint Type
2.5. Snippet by Cause
2.6. Snippet by Distribution Channel
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Osteoarthritis (OA)
3.1.1.2. Minimally Invasive Alternatives to Surgery
3.1.1.3. Rising Demand for Non-Opioid Pain Management Options
3.1.2. Restraints
3.1.2.1. Limited Long-Term Efficacy
3.1.2.2. High Treatment Costs
3.1.2.3. Regulatory Challenges
3.1.3. Opportunity
3.1.3.1. Emerging Biologic Injections
3.1.3.2. Expansion into Emerging Markets
3.1.3.3. Advances in extended-release Corticosteroids and Novel HA Formulations
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Pipeline Analysis
4.7. Patent Analysis
4.8. SWOT Analysis
4.9. Unmet Needs and Gaps
4.10. Recommended Strategies for Market Entry and Expansion
4.11. Pricing Analysis and Price Dynamics
5. GLOBAL JOINT PAIN INJECTION MARKET, BY INJECTION TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Injection Type
5.1.2. Market Attractiveness Index, By Injection Type
5.2. Hyaluronic acid (HA)*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Corticosteroids
5.4. Prolotherapy Injections
5.5. Orthobiologics
5.6. Platelet-rich Plasma (PRP) Injections
5.7. Others
6. GLOBAL JOINT PAIN INJECTION MARKET, BY JOINT TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Joint Type
6.1.2. Market Attractiveness Index, By Joint Type
6.2. Knee and Ankle*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Hip
6.4. Shoulder and Elbow
6.5. Others
7. GLOBAL JOINT PAIN INJECTION MARKET, BY CAUSE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cause
7.1.2. Market Attractiveness Index, By Cause
7.2. Osteoarthritis*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Rheumatoid arthritis
7.4. Fibromyalgia
7.5. Others
8. GLOBAL JOINT PAIN INJECTION MARKET, BY DISTRIBUTION CHANNEL
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Online Pharmacies
9. GLOBAL JOINT PAIN INJECTION MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Injection Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Joint Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cause
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.7.1. U.S.
9.2.7.2. Canada
9.2.7.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Injection Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Joint Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cause
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.7.1. Germany
9.3.7.2. UK
9.3.7.3. France
9.3.7.4. Spain
9.3.7.5. Italy
9.3.7.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Injection Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Joint Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cause
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.7.1. China
9.4.7.2. India
9.4.7.3. Japan
9.4.7.4. South Korea
9.4.7.5. Rest of Asia-Pacific
9.5. South America
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Injection Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Joint Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cause
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.7.1. Brazil
9.5.7.2. Argentina
9.5.7.3. Rest of South America
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Injection Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Joint Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cause
9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
11.1. Key Players
11.1.1. Bioventus*
11.1.2. Company Overview
11.1.2.1. Product Portfolio
11.1.2.1.1. Product Description
11.1.2.1.2. Product Key Performance Indicators (KPIs)
11.1.2.2. Financial Overview
11.1.2.2.1. Company Revenue
11.1.2.2.2. Geographical Revenue Shares
11.1.2.2.3. Revenue Forecasts
11.1.2.3. Key Developments
11.1.2.3.1. Mergers & Acquisitions
11.1.2.3.2. Key Product Development Activities
11.1.2.3.3. Regulatory Approvals, etc.
11.1.2.4. SWOT Analysis
11.1.3. Anika Therapeutics Inc
11.1.4. Zimmer Biomet
11.1.5. Dr. Reddy’s Laboratories Ltd.
11.1.6. Fidia Farmaceutici S.p.A. (LIST NOT EXHAUSTIVE)
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
LIST OF TABLES
Table 1 Global Joint Pain Injection Market Value, By Injection Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Joint Pain Injection Market Value, By Joint Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Joint Pain Injection Market Value, By Cause, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Joint Pain Injection Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Joint Pain Injection Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Joint Pain Injection Market Value, By Injection Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Joint Pain Injection Market Value, By Injection Type, 2022-2033 (US$ Billion)
Table 8 Global Joint Pain Injection Market Value, By Joint Type, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Joint Pain Injection Market Value, By Joint Type, 2022-2033 (US$ Billion)
Table 10 Global Joint Pain Injection Market Value, By Cause, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Joint Pain Injection Market Value, By Cause, 2022-2033 (US$ Billion)
Table 12 Global Joint Pain Injection Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Joint Pain Injection Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 14 Global Joint Pain Injection Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Joint Pain Injection Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Joint Pain Injection Market Value, By Injection Type, 2022-2033 (US$ Billion)
Table 17 North America Joint Pain Injection Market Value, By Joint Type, 2022-2033 (US$ Billion)
Table 18 North America Joint Pain Injection Market Value, By Cause, 2022-2033 (US$ Billion)
Table 19 North America Joint Pain Injection Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 20 North America Joint Pain Injection Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Joint Pain Injection Market Value, By Injection Type, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific Joint Pain Injection Market Value, By Joint Type, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific Joint Pain Injection Market Value, By Cause, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific Joint Pain Injection Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 25 Asia-Pacific Joint Pain Injection Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Europe Joint Pain Injection Market Value, By Injection Type, 2022-2033 (US$ Billion)
Table 27 Europe Joint Pain Injection Market Value, By Joint Type, 2022-2033 (US$ Billion)
Table 28 Europe Joint Pain Injection Market Value, By Cause, 2022-2033 (US$ Billion)
Table 29 Europe Joint Pain Injection Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 30 Europe Joint Pain Injection Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 South America Joint Pain Injection Market Value, By Injection Type, 2022-2033 (US$ Billion)
Table 32 South America Joint Pain Injection Market Value, By Joint Type, 2022-2033 (US$ Billion)
Table 33 South America Joint Pain Injection Market Value, By Cause, 2022-2033 (US$ Billion)
Table 34 South America Joint Pain Injection Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 35 South America Joint Pain Injection Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Joint Pain Injection Market Value, By Injection Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Joint Pain Injection Market Value, By Joint Type, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Joint Pain Injection Market Value, By Cause, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Joint Pain Injection Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Joint Pain Injection Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 Bioventus: Overview
Table 42 Bioventus: Product Portfolio
Table 43 Bioventus: Key Developments
Table 44 Anika Therapeutics Inc: Overview
Table 45 Anika Therapeutics Inc: Product Portfolio
Table 46 Anika Therapeutics Inc: Key Developments
Table 47 Zimmer Biomet: Overview
Table 48 Zimmer Biomet: Product Portfolio
Table 49 Zimmer Biomet: Key Developments
Table 50 Dr. Reddy’s Laboratories Ltd.: Overview
Table 51 Dr. Reddy’s Laboratories Ltd.: Product Portfolio
Table 52 Dr. Reddy’s Laboratories Ltd.: Key Developments
Table 53 Fidia Farmaceutici S.p.A.: Overview
Table 54 Fidia Farmaceutici S.p.A.: Product Portfolio
Table 55 Fidia Farmaceutici S.p.A.: Key Developments
Table 1 Global Joint Pain Injection Market Value, By Injection Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Joint Pain Injection Market Value, By Joint Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Joint Pain Injection Market Value, By Cause, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Joint Pain Injection Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Joint Pain Injection Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Joint Pain Injection Market Value, By Injection Type, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Joint Pain Injection Market Value, By Injection Type, 2022-2033 (US$ Billion)
Table 8 Global Joint Pain Injection Market Value, By Joint Type, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Joint Pain Injection Market Value, By Joint Type, 2022-2033 (US$ Billion)
Table 10 Global Joint Pain Injection Market Value, By Cause, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Joint Pain Injection Market Value, By Cause, 2022-2033 (US$ Billion)
Table 12 Global Joint Pain Injection Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Joint Pain Injection Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 14 Global Joint Pain Injection Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Joint Pain Injection Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Joint Pain Injection Market Value, By Injection Type, 2022-2033 (US$ Billion)
Table 17 North America Joint Pain Injection Market Value, By Joint Type, 2022-2033 (US$ Billion)
Table 18 North America Joint Pain Injection Market Value, By Cause, 2022-2033 (US$ Billion)
Table 19 North America Joint Pain Injection Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 20 North America Joint Pain Injection Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Joint Pain Injection Market Value, By Injection Type, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific Joint Pain Injection Market Value, By Joint Type, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific Joint Pain Injection Market Value, By Cause, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific Joint Pain Injection Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 25 Asia-Pacific Joint Pain Injection Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Europe Joint Pain Injection Market Value, By Injection Type, 2022-2033 (US$ Billion)
Table 27 Europe Joint Pain Injection Market Value, By Joint Type, 2022-2033 (US$ Billion)
Table 28 Europe Joint Pain Injection Market Value, By Cause, 2022-2033 (US$ Billion)
Table 29 Europe Joint Pain Injection Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 30 Europe Joint Pain Injection Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 South America Joint Pain Injection Market Value, By Injection Type, 2022-2033 (US$ Billion)
Table 32 South America Joint Pain Injection Market Value, By Joint Type, 2022-2033 (US$ Billion)
Table 33 South America Joint Pain Injection Market Value, By Cause, 2022-2033 (US$ Billion)
Table 34 South America Joint Pain Injection Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 35 South America Joint Pain Injection Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Joint Pain Injection Market Value, By Injection Type, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Joint Pain Injection Market Value, By Joint Type, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Joint Pain Injection Market Value, By Cause, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Joint Pain Injection Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Joint Pain Injection Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 Bioventus: Overview
Table 42 Bioventus: Product Portfolio
Table 43 Bioventus: Key Developments
Table 44 Anika Therapeutics Inc: Overview
Table 45 Anika Therapeutics Inc: Product Portfolio
Table 46 Anika Therapeutics Inc: Key Developments
Table 47 Zimmer Biomet: Overview
Table 48 Zimmer Biomet: Product Portfolio
Table 49 Zimmer Biomet: Key Developments
Table 50 Dr. Reddy’s Laboratories Ltd.: Overview
Table 51 Dr. Reddy’s Laboratories Ltd.: Product Portfolio
Table 52 Dr. Reddy’s Laboratories Ltd.: Key Developments
Table 53 Fidia Farmaceutici S.p.A.: Overview
Table 54 Fidia Farmaceutici S.p.A.: Product Portfolio
Table 55 Fidia Farmaceutici S.p.A.: Key Developments
LIST OF FIGURES
Figure 1 Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Joint Pain Injection Market Share, By Injection Type, 2024 & 2033 (%)
Figure 3 Global Joint Pain Injection Market Share, By Joint Type, 2024 & 2033 (%)
Figure 4 Global Joint Pain Injection Market Share, By Cause, 2024 & 2033 (%)
Figure 5 Global Joint Pain Injection Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 6 Global Joint Pain Injection Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Joint Pain Injection Market Y-o-Y Growth, By Injection Type, 2023-2033 (%)
Figure 8 Hyaluronic acid (HA) Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 9 Corticosteroids Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 10 Prolotherapy Injections Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 11 Orthobiologics Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 12 Platelet-rich Plasma (PRP) Injections Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 13 Others Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 14 Global Joint Pain Injection Market Y-o-Y Growth, By Joint Type, 2023-2033 (%)
Figure 15 Knee and Ankle Joint Type in Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 16 Hip Joint Type in Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 17 Shoulder and Elbow Joint Type in Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 18 Others Joint Type in Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 19 Global Joint Pain Injection Market Y-o-Y Growth, By Cause, 2023-2033 (%)
Figure 20 Osteoarthritis Cause in Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 21 Rheumatoid arthritis Cause in Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 22 Fibromyalgia Cause in Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 23 Others Cause in Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 24 Global Joint Pain Injection Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)
Figure 25 Hospital Pharmacies Distribution Channel in Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 26 Retail Pharmacies Distribution Channel in Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 27 Online Pharmacies Distribution Channel in Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 28 Global Joint Pain Injection Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 29 North America Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 30 North America Joint Pain Injection Market Share, By Injection Type, 2024 & 2033 (%)
Figure 31 North America Joint Pain Injection Market Share, By Joint Type, 2024 & 2033 (%)
Figure 32 North America Joint Pain Injection Market Share, By Cause, 2024 & 2033 (%)
Figure 33 North America Joint Pain Injection Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 34 North America Joint Pain Injection Market Share, By Country, 2024 & 2033 (%)
Figure 35 Asia-Pacific Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 36 Asia-Pacific Joint Pain Injection Market Share, By Injection Type, 2024 & 2033 (%)
Figure 37 Asia-Pacific Joint Pain Injection Market Share, By Joint Type, 2024 & 2033 (%)
Figure 38 Asia-Pacific Joint Pain Injection Market Share, By Cause, 2024 & 2033 (%)
Figure 39 Asia-Pacific Joint Pain Injection Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 40 Asia-Pacific Joint Pain Injection Market Share, By Country, 2024 & 2033 (%)
Figure 41 Europe Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 42 Europe Joint Pain Injection Market Share, By Injection Type, 2024 & 2033 (%)
Figure 43 Europe Joint Pain Injection Market Share, By Joint Type, 2024 & 2033 (%)
Figure 44 Europe Joint Pain Injection Market Share, By Cause, 2024 & 2033 (%)
Figure 45 Europe Joint Pain Injection Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 46 Europe Joint Pain Injection Market Share, By Country, 2024 & 2033 (%)
Figure 47 South America Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 48 South America Joint Pain Injection Market Share, By Injection Type, 2024 & 2033 (%)
Figure 49 South America Joint Pain Injection Market Share, By Joint Type, 2024 & 2033 (%)
Figure 50 South America Joint Pain Injection Market Share, By Cause, 2024 & 2033 (%)
Figure 51 South America Joint Pain Injection Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 52 South America Joint Pain Injection Market Share, By Country, 2024 & 2033 (%)
Figure 53 Middle East and Africa Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 54 Middle East and Africa Joint Pain Injection Market Share, By Injection Type, 2024 & 2033 (%)
Figure 55 Middle East and Africa Joint Pain Injection Market Share, By Joint Type, 2024 & 2033 (%)
Figure 56 Middle East and Africa Joint Pain Injection Market Share, By Cause, 2024 & 2033 (%)
Figure 57 Middle East and Africa Joint Pain Injection Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 58 Bioventus: Financials
Figure 59 Anika Therapeutics Inc: Financials
Figure 60 Zimmer Biomet: Financials
Figure 61 Dr. Reddy’s Laboratories Ltd.: Financials
Figure 62 Fidia Farmaceutici S.p.A.: Financials
Figure 1 Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Joint Pain Injection Market Share, By Injection Type, 2024 & 2033 (%)
Figure 3 Global Joint Pain Injection Market Share, By Joint Type, 2024 & 2033 (%)
Figure 4 Global Joint Pain Injection Market Share, By Cause, 2024 & 2033 (%)
Figure 5 Global Joint Pain Injection Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 6 Global Joint Pain Injection Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Joint Pain Injection Market Y-o-Y Growth, By Injection Type, 2023-2033 (%)
Figure 8 Hyaluronic acid (HA) Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 9 Corticosteroids Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 10 Prolotherapy Injections Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 11 Orthobiologics Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 12 Platelet-rich Plasma (PRP) Injections Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 13 Others Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 14 Global Joint Pain Injection Market Y-o-Y Growth, By Joint Type, 2023-2033 (%)
Figure 15 Knee and Ankle Joint Type in Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 16 Hip Joint Type in Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 17 Shoulder and Elbow Joint Type in Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 18 Others Joint Type in Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 19 Global Joint Pain Injection Market Y-o-Y Growth, By Cause, 2023-2033 (%)
Figure 20 Osteoarthritis Cause in Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 21 Rheumatoid arthritis Cause in Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 22 Fibromyalgia Cause in Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 23 Others Cause in Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 24 Global Joint Pain Injection Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)
Figure 25 Hospital Pharmacies Distribution Channel in Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 26 Retail Pharmacies Distribution Channel in Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 27 Online Pharmacies Distribution Channel in Global Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 28 Global Joint Pain Injection Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 29 North America Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 30 North America Joint Pain Injection Market Share, By Injection Type, 2024 & 2033 (%)
Figure 31 North America Joint Pain Injection Market Share, By Joint Type, 2024 & 2033 (%)
Figure 32 North America Joint Pain Injection Market Share, By Cause, 2024 & 2033 (%)
Figure 33 North America Joint Pain Injection Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 34 North America Joint Pain Injection Market Share, By Country, 2024 & 2033 (%)
Figure 35 Asia-Pacific Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 36 Asia-Pacific Joint Pain Injection Market Share, By Injection Type, 2024 & 2033 (%)
Figure 37 Asia-Pacific Joint Pain Injection Market Share, By Joint Type, 2024 & 2033 (%)
Figure 38 Asia-Pacific Joint Pain Injection Market Share, By Cause, 2024 & 2033 (%)
Figure 39 Asia-Pacific Joint Pain Injection Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 40 Asia-Pacific Joint Pain Injection Market Share, By Country, 2024 & 2033 (%)
Figure 41 Europe Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 42 Europe Joint Pain Injection Market Share, By Injection Type, 2024 & 2033 (%)
Figure 43 Europe Joint Pain Injection Market Share, By Joint Type, 2024 & 2033 (%)
Figure 44 Europe Joint Pain Injection Market Share, By Cause, 2024 & 2033 (%)
Figure 45 Europe Joint Pain Injection Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 46 Europe Joint Pain Injection Market Share, By Country, 2024 & 2033 (%)
Figure 47 South America Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 48 South America Joint Pain Injection Market Share, By Injection Type, 2024 & 2033 (%)
Figure 49 South America Joint Pain Injection Market Share, By Joint Type, 2024 & 2033 (%)
Figure 50 South America Joint Pain Injection Market Share, By Cause, 2024 & 2033 (%)
Figure 51 South America Joint Pain Injection Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 52 South America Joint Pain Injection Market Share, By Country, 2024 & 2033 (%)
Figure 53 Middle East and Africa Joint Pain Injection Market Value, 2022-2033 (US$ Billion)
Figure 54 Middle East and Africa Joint Pain Injection Market Share, By Injection Type, 2024 & 2033 (%)
Figure 55 Middle East and Africa Joint Pain Injection Market Share, By Joint Type, 2024 & 2033 (%)
Figure 56 Middle East and Africa Joint Pain Injection Market Share, By Cause, 2024 & 2033 (%)
Figure 57 Middle East and Africa Joint Pain Injection Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 58 Bioventus: Financials
Figure 59 Anika Therapeutics Inc: Financials
Figure 60 Zimmer Biomet: Financials
Figure 61 Dr. Reddy’s Laboratories Ltd.: Financials
Figure 62 Fidia Farmaceutici S.p.A.: Financials
